A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Condition(s) studied
Investigational drug(s) / intervention(s)
EPI-326: EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers. EPI-326 will be administered in the clinic via IV infusion.
Study summary
A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.
Eligibility
Primary outcome measure(s)
- Evaluation of the safety and tolerability of EPI-326 — Up to 3 years.
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicity (DLTs). - Determination of the recommended dose and schedule for EPI-326 administration — Up to 3 years.
Maximum tolerated dose (MTD), maximum administered dose (MAD).
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| Site 105 - START Los Angeles | Los Angeles | California | Recruiting |
| Site 104 - START New Jersey | East Brunswick | New Jersey | Recruiting |
| Site 107 - START New York - Long Island | Lake Success | New York | Recruiting |
| Sarah Cannon and HCA Research Institute | Nashville | Tennessee | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | Recruiting |
| Site 102 - START San Antonio | San Antonio | Texas | Recruiting |
| Samsung Medical Center | Seoul | South Korea | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) | Kaohsiung City | Taiwan | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07462377 on ClinicalTrials.gov ↗ ← All trials in Taiwan